Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04387461 · ClinicalTrials.gov registry record · Phase 2
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
A Phase 2 study, sponsored by CG Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT04387461 is a Phase 2 study that has completed, run by CG Oncology. The registered enrollment target is 35 participants.
The verdict
NCT04387461, a Phase 2 study, has completed, sponsored by CG Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscle invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or without Ta/T1 papillary disease.
Interventions
- BIOLOGICAL Pembrolizumab Injection
- BIOLOGICAL CG0070
- OTHER n-dodecyl-B-D-maltoside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-12-08 |
| Est. Completion | 2024-05-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04387461
The ClinicalTrials.gov registry entry for NCT04387461 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CG Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab Injection is the first listed.
NCT04387461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04387461 about?
NCT04387461 is a clinical study titled "Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin". To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscle invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or w...
What is the current status of trial NCT04387461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2020-12-08. Estimated completion is 2024-05-28.
What interventions are being tested in trial NCT04387461?
The interventions under investigation include: Pembrolizumab Injection (BIOLOGICAL), CG0070 (BIOLOGICAL), n-dodecyl-B-D-maltoside (OTHER).
Who is sponsoring clinical trial NCT04387461?
This trial is sponsored by CG Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.